Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 7/20 | 0.40 |
| ▸ | ATR | Q13535 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25519632 | 0.95 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL14726450 | 0.84 | GAA (0.47) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL22449667 | 0.81 | CYP4F2 (0.44) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL19204921 | 0.81 | CYP4F2 (0.44) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL31510943 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL21191295 | 0.80 | CYP4F2 (0.43) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL21187504 | 0.80 | RET (0.49) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL3500250 | 0.79 | CYP4F2 (0.41) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL14638243 | 0.79 | CYP4F2 (0.43) | ALDH1A1LMNAPOLBGAACYP4F2 | |
| SCHEMBL30430140 | 0.79 | CYP4F2 (0.43) | ALDH1A1LMNAPOLBGAACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2025-11-27 | — | — | US | disclosed |
| US-12435062-B2 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2025-06-05 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115925684-B | Pyrimidine derivative and preparation method and application thereof | 徐诺药业(南京)有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4482833-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Repare Therapeutics Inc. (CA) | 2025-01-01 | — | — | EP | disclosed |
| CN-118946560-A | POLO-like kinase 4 (PLK 4) inhibitors, pharmaceutical compositions, methods for their preparation and uses | 修复治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117777103-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-10035789-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018022761-A1 | SUBSTITUTED CYCLOPENTANE-AMIDES FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022761-A1 | SUBSTITUTED CYCLOPENTANE-AMIDES FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-02-01 | — | — | US | disclosed |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-02-01 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2121619-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC Immune S.A. (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035789-B2 | Compounds useful for treating disorders related to RET | RET, EYA2, HRAS | ALDH1A1 2131/4885LMNA 2937/4885POLB 1638/4885 |
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | ALDH1A1 4083/4885LMNA 1515/4885POLB 903/4885 |
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | ALDH1A1 1974/4885LMNA 591/4885POLB 4386/4885 |
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | PLK4, PLK2, PLK3 | ALDH1A1 2707/4885LMNA 1321/4885POLB 158/4885 |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | ALDH1A1 2131/4885LMNA 2937/4885POLB 1638/4885 |
| US-12435062-B2 | Amide compounds and uses thereof | ASNS, ASS1, NAT1 | ALDH1A1 610/4885LMNA 3803/4885POLB 3877/4885 |
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, NAT1, AADAC | ALDH1A1 585/4885LMNA 3547/4885POLB 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.